Table 2.
Baseline characteristics of patients according with the autoimmunity status (n1 = 96; n2 = 288).
| Baseline characteristics | Cases (n1 = 96) |
Controls (n2 = 288) |
p-value |
|---|---|---|---|
| Age at evaluation (years) | 38.7 ± 6.1 | 38.7 ± 6.1 | 0.987 |
| Age at diagnostic LS (years) | 31.1 ± 6.2 | 30.1 ± 5.4 | 0.761 |
| Age at symptoms onset (years) | 16 [14–20] | 18 [13–25] | 0.960 |
| Time from LS (years) | 7.7 ± 5.9 | 8.0 ± 5.7 | 0.703 |
| Number of surgical procedures | 1 [1–1] | 1 [1–1] | 0.166 |
| Number of clinical evaluations | 2 [2–3] | 2 [1–2] | 0.0001 |
| r-AFS stage | |||
| I | 2 (2.1%) | 10 (3.5%) | 0.495 |
| II | 7 (7.3%) | 30 (10.5%) | 0.364 |
| III | 32 (33.3%) | 150 (52.3%) | 0.001 |
| IV | 55 (57.3%) | 97 (25.3%) | 0.000 |
| Type of endometriosis | |||
| OMA | 75 (78.1%) | 193 (67.2%) | 0.096 |
| SPE | 45 (46.9%) | 175 (61%) | 0.016 |
| DIE | 43 (44.8%) | 97 (33.8%) | 0.053 |
| Hormone therapy | |||
| Any | 43 (44.8%) | 137 (47.7%) | 0.617 |
| None | 32 (33.3%) | 92 (32.1%) | 0.817 |
| Not known | 21 (21.9%) | 58 (20.2%) | 0.727 |
| Concomitant autoimmune disease | 0.000 | ||
| None | 287 (100%) | ||
| ATD | 57 (59.4%) | ||
| T1D | 10 (10.4%) | ||
| IBD | 9 (9.4%) | ||
| CLD | 1 (1%) | ||
| LES/APS | 5 (5.2%) | ||
| RA | 6 (6.3%) | ||
| Fibromyalgia | 2 (2.1%) | ||
| SS | 1 (1%) | ||
| MS | 4 (4.2%) | ||
| Psoriasis | 1 (1%) | ||
| Multiple | 15 (15.6%) | ||
Values are mean ± SD or median [IQR] or n (%).
Bold values denote statistical significance at the p < 0.05 level.
LS, laparoscopic surgery; r-AFS, revised American Fertility Society; OMA, ovarian endometrioma; SPE, superficial peritoneal endometriosis; DIE, deep infiltrating endometriosis; ATD, autoimmune thyroid disorders; T1D, type 1 diabetes; IBD, inflammatory bowel diseases; CLD, coeliac disease; SLE, systemic lupus erythematosus; APS, antiphospholipid syndrome, RA, rheumatoid arthritis; SS, systemic sclerosis; MS, multiple sclerosis.